North America
Tatiana Campello reflects on 30 years of practising at the firm, and urges women IP attorneys to think beyond the day-to-day
Latham & Watkins bolstered its IP litigation bench in California with the addition of Kieran Kieckhefer, as partner demand for trial-ready expertise shows no sign of slowing
With the launch of a new patent eligibility AI tool, Sterne Kessler is leading a growing movement of law firms taking AI development into their own hands
Attorneys contemplate whether clients using AI for legal guidance is beneficial to attorney-client relationships or more of a nuisance
Sponsored
Sponsored
-
Sponsored by Becerril, Coca & BecerrilLuis Emilio Moncada of Becerril, Coca & Becerril explains why provisional measures are an increasingly valuable mechanism under Mexican intellectual property law as the country prepares to co-host the football World Cup -
Sponsored by Becerril, Coca & BecerrilFernanda Villalobos of Becerril, Coca & Becerril explains how Mexican trademark law now allows descriptive signs to acquire protection through market use and consumer recognition
-
Sponsored by Becerril, Coca & BecerrilStephania Cardiel of Becerril, Coca & Becerril examines how recent reforms signal a regional move towards faster, more internationally aligned innovation systems
-
Sponsored by Bird & BirdAnne-Raphaëlle Aubry of Bird & Bird explains how Section 1782 and Rule of Procedure 190 offer different pathways for cross-border evidence gathering in European patent disputes, highlighting timing, scope, and strategic considerations for litigants
-
Sponsored by Becerril, Coca & BecerrilMonica Sánchez of Becerril, Coca & Becerril explains how the Mexican intellectual property framework, including compulsory licences and the Bolar clause, works alongside emerging technologies to balance pharmaceutical innovation with public health access
-
Sponsored by Becerril, Coca & BecerrilCarlos Hernández León of Becerril, Coca & Becerril outlines how Mexico’s shift from NAFTA-based patent term extensions to the new SPC regime affects patent holders, particularly in pharmaceuticals, and the strategic steps to secure additional protection
North American Jurisdictions